europeanpharmaceuticalreviewMarch 26, 2020
According to a new report, India will establish an almost 100-billion-rupee ($1.3 billion) fund to aid pharmaceutical companies in the manufacturing of active pharmaceutical ingredients (API).
Published in Bloomberg, the report highlights that the disruptions to the supply chain because of the COVID-19 coronavirus revealed the extent to which India relies on China for APIs and how easily medicine shortages could occur.
Reportedly, a government statement outlined that the funding will go towards infrastructure for drug manufacturing facilities and financial incentives of up to 20 percent incremental sales value over the next eight years.
As the outlet highlights, India imports almost 70 percent of its APIs from China, with many sourced from the Hubei province – the epicentre of the COVID-19 outbreak, leading to its decision to invest inwardly.
Register as Visitor to CPhI China 2020!
-----------------------------------------------------------------------
Editor's Note:
En-CPhI.CN is a vertical B2B online trade platform serving the pharmaceutical industry,
for any copyright disputes involved in the articles,
please email: Julia.Zhang@imsinoexpo.com to motify or remove the content.
Contact Us
Tel: (+86) 400 610 1188
WhatsApp/Telegram/Wechat: +86 13621645194
Follow Us: